The primary purpose of this research is to see if the use of cobimetinib (the study drug) may be effective for the treatment of chronic myelomonocytic leukemia (CMML). Researchers will also evaluate the safety, disease response, and long-term effectiveness of the study drug.

The goal of this research study is to find out how well experimental drug pemigatinib works and if it's safe when used after standard treatment for Acute Myeloid Leukemia (AML) in people who have a particular type of genetic risk called adverse or intermediate risk cytogenetics. Pemigatinib works by targeting something called FGFR (fibroblast growth factor receptor), which can be involved in the growth of leukemia cells. Different patients may have different ways their leukemia cells grow, and these ways can even change over time. The study aims to see if pemigatinib can help in treating AML by blocking this growth factor receptor.

The purpose of the study is to learn if Gilteritinib (the study drug), given in combination with Azacitidine and Venetoclax, is a safe and effective regimen for patients recently diagnosed with Acute Myeloid Leukemia (AML) who are not eligible for intensive chemotherapy. This study is for patients who have FMS-like tyrosine kinase 3 (FLT3) - mutated AML that has been recently diagnosed and have never been treated before for this condition.

The purpose of this study is to learn about the effects of an investigational new study drug, SGR-2921, that is being developed as an anti-cancer agent. The cancer cells contain a protein called CDC7, which helps cancer cells survive and replicate. In this study, we will examine if SGR-2921 will target CDC7 and inhibit it, or stop it from working, ultimately leading to cancer cell death.

The purpose of this study is to test the levels of the investigational drug ASTX030 in your blood, including if food has an effect (Phase 1B only), the safety and tolerability of the drugs, and how participants respond to the drug. ASTX030 is a combination of two medicines, azacitidine and cedazuridine, given by mouth.

The purpose of the study is to learn more about an investigational drug called revumenib, otherwise known as SNDX-5613, (referred to as “the study drug”). We are hoping to find out what is the best dose of the study drug taken with other cancer drugs, and to find out what side effects happen after you take this drug.

The purpose of the study is to learn about the safety and tolerability of the study drug (INCB057643) as a single agent (monotherapy) or in combination with Ruxolitinib. This is an open-label study, which means that both you and your investigator will know what you are receiving. This study is for patients who have relapsed or refractory Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Myeloproliferative Neoplasm, or Essential Thrombocythemia who have received at least 1 prior line of treatment.

The purpose of this study is to test the safety of a study drug called INCB160058 for people with myelofibrosis who have the JAK2V617F mutation. This drug has been tested in animals but not yet in people. This study tests different doses of the drug to see which dose is safer in people. When this study starts, another study in healthy volunteers may have started. You may ask your doctor for more information. The use of the study drug, INCB160058 is experimental. It has not been approved by the FDA because we do not know enough about it.

The purpose of the study is to learn more about SNDX-5613 and if it has an effect on acute leukemia that has returned or not responded to treatment with a mixed lineage leukemia gene rearrangement (MLLr) or a nucleophosmin 1 (NPM1c) mutation. We are hoping to find out what is the best dose of SNDX-5613, as well as to determine what side effects arise from this experimental drug. This study will also look at whether the study drug may slow the progression of your cancer. It will also study whether there is something in your blood that can be measured to assess how the study drug will work and/or predict how well future patients may respond to the therapy. It will also investigate how quickly and to what extent the study drug is absorbed and eliminated from the body (this is called pharmacokinetics).